Good evening :)
$
₹
Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc

ENTA

NASDAQ
Asset Logo

Enanta Pharmaceuticals Inc

ENTA

NASDAQ
$11.342.36% (-0.27)
$
₹
$11.342.36% (-0.27)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $329.4M the stock is ranked 3664

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.44
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.42
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-96.89%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 6 analysts reports

Buy
6 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+87.89%

Earnings Growth

+40.14%

Rev. Growth

-2.03%

See Detailed Forecast

Company Profile

Company Profile

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.45
80.45
1Y Return
24.54%
24.54%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.22
27.22
1Y Return
49.15%
49.15%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.41%
29.41%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.37
30.37
1Y Return
25.49%
25.49%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
654.67%
654.67%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 87.89% growth, versus a trailing 3-year CAGR of 9.09%.

2026
Current$11.62Baseline
Analyst Target - 1 year
Target$21.83+87.89%

All values in $

202220232024202520262027$16.67$28.17$39.67Target+87.89%
2026
Current$11.62Baseline
Analyst Target - 1 year
Target$21.83+87.89%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -2.03% growth, versus a trailing 3-year CAGR of -8.82%.

2025
Current$65.32Baseline
Forecast for Sep 2026
High$66.13+1.24%
Average$63.99-2.03%
Low$61-6.62%

All values in $ Million

20212022202320242025202697.0786.1679.2067.6365.32Low-6.62%Average-2.03%High+1.24%
2025
Current$65.32Baseline
Forecast for Sep 2026
High$66.13+1.24%
Average$63.99-2.03%
Low$61-6.62%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-3.83Baseline
Forecast for Sep 2026
High$-2.09+45.43%
Average$-2.29+40.14%
Low$-2.49+34.99%

All values in $

202120222023202420252026-3.91-5.91-6.37-5.48-3.83Low+34.99%Average+40.14%High+45.43%
2025
Current$-3.83Baseline
Forecast for Sep 2026
High$-2.09+45.43%
Average$-2.29+40.14%
Low$-2.49+34.99%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

15.1
-18.7
18.6
-11.9
17.1
-13
14.3
-19.5
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue17.0517.9714.6016.9514.9218.3115.1218.6117.1514.35
Net Income-31.15-22.65-28.82-22.29-22.64-18.25-18.7-11.93-13.09-19.50
Net Profit Margin-182.69%-126.08%-197.32%-131.43%-151.70%-99.67%-123.63%-64.13%-76.29%-135.81%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Enanta Pharmaceuticals Inc -3.440
AbbVie Inc80.4550.450.54
Amgen Inc27.2218.782.45
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare ENTA with any stock or ETF
Compare ENTA with any stock or ETF
Comparing from
ENTA
ABBV
AMGN
Loading...

Frequently asked questions

  1. Enanta Pharmaceuticals Inc (ENTA) share price today is $11.34 as of October 23, 2026 at 11:26 PM IST. The stock touched a day high of $11.44 and a day low of $10.97.

  2. Enanta Pharmaceuticals Inc stock trades on NASDAQ under the ticker symbol ENTA.

  3. Enanta Pharmaceuticals Inc's market capitalization is $329.4M as of October 23, 2026 at 11:26 PM IST.

  4. Enanta Pharmaceuticals Inc's price-to-earnings (P/E) ratio is N/A as of October 23, 2026.

  5. Enanta Pharmaceuticals Inc's price-to-book (P/B) ratio is 3.44 as of October 23, 2026.

  6. Yes, You can buy Enanta Pharmaceuticals Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Enanta Pharmaceuticals Inc shares in three steps: 1. Search Enanta Pharmaceuticals Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Enanta Pharmaceuticals Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Enanta Pharmaceuticals Inc (ENTA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.8814 shares at the current price of $11.34.

Loading...